Analyst Reco. Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Delayed Nasdaq Other stock markets 02:26:31 2024-05-01 pm EDT			5-day change	1st Jan Change
3.04 ^USD	+4.47%		+2.70%	-8.43%

Apr. 12	Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating	MT
Apr. 11	Syncona agrees to sell stake in investee company for GBP7.4 million	AN

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating	Apr. 12	MT
Canaccord Genuity Adjusts Price Target on Century Therapeutics to $24 From $22, Maintains Buy Rating	Mar. 15	MT
JPMorgan Downgrades Century Therapeutics to Neutral From Overweight, Adjusts Price Target to $5 From $28	23-08-28	MT
HC Wainwright Adjusts Century Therapeutics' Price Target to $13 From $17, Keeps Buy Rating	23-08-10	MT
Chardan Adjusts Price Target on Century Therapeutics to $17 From $19, Keeps Buy Rating	23-08-10	MT
HC Wainwright Trims Price Target on Century Therapeutics to $17 From $19, Maintains Buy Rating	23-03-17	MT
SVB Securities Adjusts Century Therapeutics' Price Target to $14 From $20, Keeps Outperform Rating	23-01-06	MT
HC Wainwright Adjusts Price Target on Century Therapeutics to $19 From $25, Maintains Buy Rating	23-01-06	MT
Piper Sandler Adjusts Century Therapeutics Price Target to $14 From $24, Maintains Overweight Rating	23-01-06	MT
EF Hutton Initiates Century Therapeutics at Buy With $18 Price Target	23-01-05	MT
Chardan Initiates Century Therapeutics With Buy Rating, $19 Price Target	22-12-27	MT
Guggenheim Initiates Century Therapeutics at Buy With $15 Price Target	22-10-31	MT
Canaccord Genuity Initiates Century Therapeutics at Buy with $28 Price Target	22-10-10	MT
HC Wainwright Starts Century Therapeutics at Buy With $27 Price Target	22-05-23	MT
Piper Sandler Adjusts Century Therapeutics' Price Target to $22 From $38, Reiterates Overweight Rating	22-05-17	MT
William Blair Initiates Coverage on Century Therapeutics With Market Perform Rating	22-05-12	MT
SVB Leerink Adjusts Century Therapeutics' Price Target to $27 from $32, Keeps Outperform Rating	22-04-29	MT
SVB Leerink Adjusts Century Therapeutics' Price Target to $32 from $33, Keeps Outperform Rating	21-11-19	MT
CENTURY THERAPEUTICS : SVB Leerink Initiates Coverage on Century Therapeutics With Outperform Rating, $33 Price Target	21-07-13	MT
CENTURY THERAPEUTICS : JPMorgan Starts Century Therapeutics at Overweight With $40 Price Target	21-07-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Analyst Reco.

Filters